ArticleCancer immunology, immunotherapy : CII2021

Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery.

Michihisa Kono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.